Lisa Astor
Articles
Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
January 08, 2023
Article
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
Rusfertide Leads to Controlled Hematocrit Levels and Fewer Phlebotomies in Polycythemia Vera
October 09, 2022
Article
Following treatment with rusfertide, patients with polycythemia vera were able to significantly reduce their need for blood draws.
Frontline Panitumumab/mFOLFOX Elicits Longest Overall Survival To-Date in RAS Wild-Type Metastatic CRC
June 18, 2022
Article
Phase 3 findings showed that panitumumab plus mFOLFOX significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer.
Frontline Bevacizumab Prolongs PFS, OS in Ovarian Clear Cell Carcinoma
June 11, 2022
Article
Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.
Patients With RAS Wild-Type Metastatic CRC Benefit from Panitumumab/mFOLFOX
June 05, 2022
Article
Panitumumab with mFOLFOX demonstrated a clinical benefit for patients with left-sided RAS wild-type metastatic colorectal cancer in the PARADIGM trial (NCT02394795).
Niraparib, Abiraterone, and Prednisone Triplet Shows Efficacy, Safety in mCRPC With HRR Gene Alterations
May 19, 2022
Article
The combination of PARP inhibition and androgen receptor targeted therapy was found to be tolerable in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Frontline Belzutifan Associated with Meaningful Clinical Activity in Treatment of VHL-Associated RCC
July 09, 2021
Article
A phase 2 study reported clinical efficacy from the use of frontline belzutifan in patients with Von-Hippel Lindau (VHL).
Lifileucel Proves Efficacy in Pretreated Advanced Melanoma
April 12, 2021
Article
Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.
Study Highlights Racial Disparities in Blood Cancer Diagnoses, Outcomes
June 22, 2020
Article
Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes. A population study presented in a press program ahead of the 2020 AACR Virtual Annual Meeting II revealed the health disparities between these 2 populations, including for patients living near the US/Mexico border.
Recent Chemotherapy May Increase COVID-19 Mortality Risk for Patients With Thoracic Cancer
May 29, 2020
Article
Chemotherapy administered within 3 months of a diagnosis of coronavirus disease 2019 (COVID-19) increased the risk of death in patients with thoracic cancer, according to findings from the global TERAVOLT Consortium registry.